KLCM Advisors Inc. Sells 17,799 Shares of Bristol Myers Squibb Company $BMY

Key Points

• KLCM Advisors trimmed its stake in Bristol Myers Squibb by 5.2%, selling 17,799 shares and now holds 321,868 shares worth about $14.52 million (BMY is 1.4% of its portfolio and its 20th-largest holding).
• Bristol Myers Squibb missed quarterly EPS at $1.26 versus a $1.65 consensus (revenue was $12.50B, slightly above estimates), and it set FY2026 guidance of $6.05–$6.35 EPS
• The company declared a quarterly dividend of $0.63 per share (annualized $2.52) producing a 4.2% yield; the ex-dividend date is April 2 and the payment date is May 1.

KLCM Advisors Inc. reduced its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 5.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 321,868 shares of the biopharmaceutical company's stock after selling 17,799 shares during the period. Bristol Myers Squibb makes up 1.4% of KLCM Advisors Inc.'s portfolio, making the stock its 20th biggest holding. KLCM Advisors Inc.'s holdings in Bristol Myers Squibb were worth $14,516,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Darwin Wealth Management LLC purchased a new position in Bristol Myers Squibb in the second quarter worth $25,000. Harbor Capital Advisors Inc. grew its holdings in shares of Bristol Myers Squibb by 107.2% in the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 313 shares during the last quarter. Total Investment Management Inc. purchased a new position in shares of Bristol Myers Squibb in the second quarter valued at about $38,000. Twin Peaks Wealth Advisors LLC bought a new position in Bristol Myers Squibb during the 2nd quarter valued at approximately $40,000. Finally, Bank of Jackson Hole Trust lifted its holdings in Bristol Myers Squibb by 352.2% in the 3rd quarter. Bank of Jackson Hole Trust now owns 1,040 shares of the biopharmaceutical company's stock worth $47,000 after buying an additional 810 shares during the period. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol Myers Squibb Stock Down 0.3%

NYSE:BMY opened at $59.97 on Thursday. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The firm's 50-day moving average price is $58.02 and its 200-day moving average price is $51.27. The company has a market capitalization of $122.12 billion, a PE ratio of 17.38, a P/E/G ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. During the same period in the previous year, the firm earned $1.67 EPS. The company's revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is 73.04%.

Analysts Set New Price Targets

Several research firms have recently issued reports on BMY. HSBC reissued a "hold" rating and set a $53.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. UBS Group reissued a "buy" rating and set a $70.00 price objective on shares of Bristol Myers Squibb in a research report on Friday, March 6th. BMO Capital Markets reaffirmed a "market perform" rating on shares of Bristol Myers Squibb in a research report on Monday, November 17th. Scotiabank reaffirmed a "sector perform" rating and set a $60.00 target price (up from $53.00) on shares of Bristol Myers Squibb in a research note on Friday, January 9th. Finally, The Goldman Sachs Group reissued a "neutral" rating and issued a $57.00 price target (up from $51.00) on shares of Bristol Myers Squibb in a research note on Tuesday, December 2nd. Nine research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $61.00.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.